ARGX Live signals | Maximize Profits with Getagraph.com

BUY 100 min ago

@ $370.88

Issued: 25 Apr 2024 @ 15:51

Return: -0.61%

Previous signal: Apr 25 - 10:31

Previous signal: Sell

Return: -0.97 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 2.06% compare to its pairs and should correct upwards.

Stats
Today's Volume	279 900
Average Volume	289 535
Market Cap	21.91B
EPS	$0 ( 2024-02-29 )
Next earnings date	( $-0.680 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-71.16
ATR14	$10.41 (2.82%)

Correlation (AI algo v.1.1b): Undervalued: 2.06% $376.36 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.05 (neutral)

Short: -0.92 (very strong negative)

Signal:(24) Possible Trading Opportunity Present (swing)

argenx SE Correlation

10 Most Positive Correlations
MDLZ	0.898
VRTX	0.888
PLSE	0.885
NLTX	0.885
GRTX	0.881
CWST	0.878
ARCT	0.876
CRVL	0.872
CUE	0.872
HBIO	0.872

10 Most Negative Correlations
FFBW	-0.915
HALL	-0.903
HTBI	-0.895
SATS	-0.893
LKFN	-0.888
IBEX	-0.886
OBT	-0.886
HSII	-0.882
VC	-0.88
SIDU	-0.878

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

argenx SE Correlation - Currency/Commodity

-0.30
( neutral )

-0.46
( neutral )

0.65
( weak )

-0.61
( weak negative )

0.34
( neutral )

-0.03
( neutral )

argenx SE Financials

Annual	2023
Revenue:	$1.23B
Gross Profit:	$1.11B (90.39 %)
EPS:	$-5.16

Q4	2023
Revenue:	$407.43M
Gross Profit:	$264.42M (64.90 %)
EPS:	$-1.700

Q3	2023
Revenue:	$329.79M
Gross Profit:	$293.79M (89.08 %)
EPS:	$-1.250

Q2	2023
Revenue:	$270.55M
Gross Profit:	$246.53M (91.12 %)
EPS:	$-1.690

Financial Reports:

No articles found.

argenx SE

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.